More people in the UK are at risk of a hereditary form of cardiac amyloidosis, a potentially fatal heart condition, than previously thought, according to a new study led by researchers at UCL (University College London) and Queen Mary University of London.
Phathom’s first campaign for acid blocker Voquezna is the latest to use telehealth to reach potential patients directly
Phathom Pharmaceuticals today debuted its first effort for erosive esophagitis treatment Voquezna with a splashy direct-to-consumer campaign including a telehealth option. The “Kick Some Acid”
March 27, 2024